All In Biotech

Drug Trial Radar · NCT07028268

A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors

A Multicenter, Randomized, Double-Blind, Positively Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Jun 24, 2025

Primary completion

Dec 2025

Study completion May 2027

Sponsor

Sponsor type
Industry
First posted
Jun 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy, and safety of SHR-2017 Injection in Patients with Bone Metastases from Solid Tumors. To explore the reasonable dosage of SHR-2017 Injection for Bone Metastases from Solid Tumors

Conditions

  • For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors

Interventions

  • SHR-2017、Denosumab placeboDrug

    SHR-2017; high dose ;Denosumab placebo

  • SHR-2017、Denosumab placeboDrug

    SHR-2017; low dose ;Denosumab placebo

  • Denosumab;SHR-2017 placeboDrug

    Denosumab;SHR-2017 placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to pain reliefTime frame: randomization to 48 weeks after administration
  2. percentage of change in the bone turnover marker urine N-telopeptide corrected for urine creatinine (uNTx/Cr) from baseline to study week 13Time frame: randomization to 13 weeks after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.